Cargando…

Neural substrates of cognitive impairment in a NMDAR hypofunction mouse model of schizophrenia and partial rescue by risperidone

N-methyl D-aspartate receptor (NMDAR) hypofunction is a pathophysiological mechanism relevant for schizophrenia. Acute administration of the NMDAR antagonist phencyclidine (PCP) induces psychosis in patients and animals while subchronic PCP (sPCP) produces cognitive dysfunction for weeks. We investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgado-Sallent, Cristina, Gener, Thomas, Nebot, Pau, López-Cabezón, Cristina, Puig, M. Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104169/ https://www.ncbi.nlm.nih.gov/pubmed/37066076 http://dx.doi.org/10.3389/fncel.2023.1152248

Ejemplares similares

NMDAR Hypofunction Animal Models of Schizophrenia
por: Lee, Gloria, et al.
Publicado: (2019)

Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
por: Wu, Qiongqiong, et al.
Publicado: (2021)

Subunit-specific NMDAR antagonism dissociates schizophrenia subtype-relevant oscillopathies associated with frontal hypofunction and hippocampal hyperfunction
por: Pittman-Polletta, Benjamin, et al.
Publicado: (2018)

NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: A newly identified correlation and its effects in schizophrenia
por: Alherz, Fatemah, et al.
Publicado: (2017)

Top-Down Suppression of Sensory Cortex in an NMDAR Hypofunction Model of Psychosis
por: Ranson, Adam, et al.
Publicado: (2019)

GABA(B)-mediated rescue of altered excitatory–inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction
por: Gandal, M J, et al.
Publicado: (2012)

Altered avalanche dynamics in a developmental NMDAR hypofunction model of cognitive impairment
por: Seshadri, Saurav, et al.
Publicado: (2018)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Reversible Photocontrol of Dopaminergic Transmission in Wild-Type Animals
por: Matera, Carlo, et al.
Publicado: (2022)

In utero gene therapy rescues microcephaly caused by Pqbp1-hypofunction in neural stem progenitor cells
por: Ito, H, et al.
Publicado: (2015)

Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates
por: Bellotti, Elena, et al.
Publicado: (2022)

Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia
por: Kim, Seong-Wook, et al.
Publicado: (2015)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

The role of NMDAR antibody in the etiopathogenesis of schizophrenia
por: Timucin, Damla, et al.
Publicado: (2016)

Chemogenetic Activation of Prefrontal Cortex in Shank3-Deficient Mice Ameliorates Social Deficits, NMDAR Hypofunction, and Sgk2 Downregulation
por: Qin, Luye, et al.
Publicado: (2019)

Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia
por: Kehrer, Colin, et al.
Publicado: (2008)

NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
por: Snyder, Melissa A., et al.
Publicado: (2013)

Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
por: Nakazawa, Kazu, et al.
Publicado: (2017)

Molecular Basis of GABA Hypofunction in Adolescent Schizophrenia-Like Animals
por: Wang, Xiaodan, et al.
Publicado: (2021)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

Risperidone Associated Paralytic Ileus in Schizophrenia
por: Ramamourthy, Parthasarathy, et al.
Publicado: (2013)

38. DO NMDAR ANTIBODIES CAUSE SCHIZOPHRENIA?
por: Lennox, Belinda
Publicado: (2018)

Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
por: Weickert, C S, et al.
Publicado: (2013)

mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia
por: Wang, Hoau-Yan, et al.
Publicado: (2018)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011)

Replenished microglia partially rescue schizophrenia-related stress response
por: Yan, Ling, et al.
Publicado: (2023)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Anti-NMDAR antibodies as a new piece in schizophrenia’s puzzle
por: Teixeira, Antonio L, et al.
Publicado: (2017)

Contribution of NMDA Receptor Hypofunction in Prefrontal and Cortical Excitatory Neurons to Schizophrenia-Like Phenotypes
por: Rompala, Gregory R., et al.
Publicado: (2013)

Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction
por: Nakao, Kazuhito, et al.
Publicado: (2019)

Aberrant maturation and connectivity of prefrontal cortex in schizophrenia – contribution of NMDA receptor development and hypofunction
por: Gao, Wen-Jun, et al.
Publicado: (2022)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Neural substrates underlying delusions in schizophrenia
por: Zhu, Jiajia, et al.
Publicado: (2016)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n80uec2bkot1jd27egkne40p1s